A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

NCT05259917 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema

Interventions

DRUG: Placebo
DRUG: KVD900 600 mg
DRUG: KVD900 300 mg

Sponsor

KalVista Pharmaceuticals, Ltd.